To print this article, all you need is to be registered or login on Mondaq.com.
Jonathan was the lead author on behalf of the Boston Patent Law
Association s (BPLA s) Patent Office Practice and Diversity
& Inclusion Committees of a February 2021 Response to USPTO Request for
Comments on developing a national strategy to build a more
demographically, geographically and economically inclusive
innovation ecosystem. The Response provided answers to some of the
seventeen questions posed in the Request, including on how the
USPTO can provide training and outreach to populations of potential
innovators and future IP practitioners to help bring much needed
To print this article, all you need is to be registered or login on Mondaq.com.
As I have written about previously (articles here and here ), there is a growing body of case
law defining the issues that are, and are not, appealable after the
PTAB determines to institute an IPR. What s not appealable
includes, for example, the PTAB s determination as to whether
an IPR petition meets 35 U.S.C. § 312(a)(3) s sufficiency
requirement; whether, under 35 U.S.C. § 312(a)(2), the PTAB
appropriately instituted an IPR notwithstanding a
real-party-in-interest (RPI) dispute; and whether an IPR petition
is time-barred under 35 U.S.C. § 315(b) as addressed
Patent protection barriers not holding back vaccine production: drug groups say
Reuters | Mar 09, 2021 08:47 PM EST A woman holds a small bottle labelled with a Coronavirus COVID-19 Vaccine sticker in this illustration taken, (Photo : REUTERS/Dado Ruvic/File Photo)
Manufacturing capacity and ingredients shortages are the main bottlenecks to expanding COVID-19 vaccine production, several global drug groups said on Tuesday, not patents that some critics are demanding be removed. IP (intellectual property) rights is not the issue, said Thomas Cueni, who heads the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
Advertisement
Like Us on Facebook The bottlenecks are the capacity, the scarcity of raw materials, scarcity of ingredients, and it is about the know-how.
[links to sources at this URL]
Planning documents for the 2021 United Nations Food Systems Summit shed new light on the agenda behind the controversial food summit that hundreds of farmers’ and human rights groups are boycotting. The groups say agribusiness interests and elite foundations are dominating the process to push through an agenda that would enable the exploitation of global food systems, and especially Africa.
The documents, including a background paper prepared for summit dialogues and a draft policy brief for the summit, bring into focus “plans for the massive industrialization of Africa’s food systems,” said Mariam Mayet, executive director of the African Centre for Biodiversity (ACB), who provided the documents to U.S. Right to Know.